Daniel S. Duffy Appointed New CEO of Camargo Pharmaceutical Services, LLC

Stocks and Financial Services Press Releases Wednesday May 2, 2018 08:05
CINCINNATI--2 May--PRNewswire/InfoQuest

Camargo Pharmaceutical Services, LLC, ("Camargo") the global leader in 505(b)(2) drug development and global equivalents, today announced the appointment of Daniel S. Duffy as new Chief Executive Officer. Kenneth V. Phelps, Founder and President, will continue to be the visionary ambassador for the company, building the industry and driving new opportunities for Camargo.

Camargo has been instrumental in helping global pharmaceutical companies identify, develop, and obtain numerous 505(b)(2) NDA approvals. Drugs developed through this pathway have benefited countless lives in the U.S. People worldwide benefit from drugs that have been improved.

"It has been an honor to lead this organization for 15 years and I am looking forward to expanding Camargo's impact globally. I am happy Dan is joining us to expand the organization to support this vision," said Phelps.

Dan brings over 20 years of experience in biopharma and strategic management consulting. Dan was most recently the Vice President and General Manager at McKesson Specialty Health. While there, he developed a differentiated specialty pharmacy model with Centers of Excellence around oncology, neurology and complex care, patient assistance and investigational product (clinical trials). Dan holds a Master of Business Administration from the University of North Carolina Kenan-Flagler School of Business and a Bachelor of Business Administration from Kent State University.

"I am grateful for the vote of confidence and the opportunity to be part of the Camargo family. Camargo is filled with exceptionally smart and capable people who are passionate about improving medicines that serve our community," said Duffy.

ABOUT CAMARGO PHARMACEUTICAL SERVICES, LLC.

Camargo Pharmaceutical Services, LLC, headquartered in Cincinnati, OH, was founded in 2003 by Kenneth V. Phelps (President and Founder) and Dr. Ruth Stevens (Chief Scientific Officer and Founder). Camargo provides comprehensive drug development services and specializes in the 505(b)(2) approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory, and commercial viability of product development opportunities, Camargo builds and executes robust development plans that align with business strategies and ensures regulatory agency buy-in every step of the way. Routinely holding three to six meetings a month with the Food and Drug Administration (FDA), Camargo works with product developers across more than 25 countries. For more about Camargo, visit http://camargopharma.com .

Logo - https://mma.prnewswire.com/media/465303/Camargo_FullColor_Logo.jpg

Latest Press Release

PTG reveals business plan in Golden Pig Year Targeting revenue and volume growth by 20% Gearing up for expansion to 2,000 service stations and joining up with business partners to create new customer experiences

"PTG Energy" targets 2019 revenue and volume growth of 20%, aiming to increase EBITDA by 40%-50% and expand service stations to 2,000 with planned investment of 3.5 billion baht in order to maintain the second position in retailed oil market share. Mr....

Photo Release: EXIM Thailand Celebrates 25th Anniversary Inviting Public and Private Sectors to Donate to Chakri Naruebodindra Medical Institute

Mr. Adul Chotinisakorn (third right), Director of Export-Import Bank of Thailand (EXIM Thailand), together with the Bank's senior management welcomed executives from private and public agencies on the occasion of EXIM Thailand's 25th anniversary at EXIM...

Prudential Thailand launches PRUsuper a unique and flexible solution targeting customers who dont like insurance

Prudential Life Assurance (Thailand) Public Company Limited ("Prudential Thailand") has launched PRUsuper link, a unique and flexible investment-linked insurance product that was developed based on the true voice of customers through an online customer...

Bangkok Bank approved that the dividend payment be paid at the rate of Baht 6.50 per ordinary share

Bangkok Bank approved that the dividend payment for the operating results of the year 2018 be paid at the rate of Baht 6.50 per ordinary share and resolved to convene the 26th annual ordinary meeting of shareholders on April 12, 2019. Bangkok Bank...

PTT Reveals 2018 Performance, Creating Energy Security, Tackling Changes for Sustainable Future,

Strengthening infrastructure, developing new businesses, raising competitive edge, along with improving people's quality of life and conserving environment, PTT grants 82.220 billion Baht of its revenues to the government as its tax payment. Mr. Chansin...

Related Topics